This article is more than 5 years old. Information may no longer be current.
Bristol-Myers Squibb launches subcutaneous autoinjector of abatacept for patients with RA
Click Here to Manage Email Alerts
Bristol-Myers Squibb Company announced the commercial launch of the Orencia ClickJect, a self-administered autoinjector for adults with moderate to severe rheumatoid arthritis.
According to a company press release, the Orencia ClickJect administers 125 mg of subcutaneous abatacept (Orencia) with push-button operation and injection confirmation, which may reduce user errors. Orencia reportedly is the only rheumatoid arthritis biologic that can be administered in three ways, including IV infusion, prefilled syringe and the autoinjector.
“Today’s launch of the Orencia ClickJect is an example of our continued commitment to offering patients with moderate to severe rheumatoid arthritis a treatment option that may be appropriate for them, now available as an autoinjector,” Chris Boerner, head of the U.S. commercial at Bristol-Myers Squibb, said in the release. “This approval offers more options for health care providers and members of the arthritis community to consider when selecting the optimal treatment and administration option for each individual.”
Reference: